Literature DB >> 28361371

Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.

Mira-Lynn Chavanon1,2,3, Simone Inkrot4, Christine Zelenak4, Elvis Tahirovic4,5, Dragana Stanojevic6, Svetlana Apostolovic6, Aleksandra Sljivic7,8, Arsen D Ristic8,9, Dragan Matic8,10, Goran Loncar8,11, Jovan Veskovic4,5, Marija Zdravkovic12, Mitja Lainscak13, Burkert Pieske4,5, Christoph Herrmann-Lingen14,15, Hans-Dirk Düngen4,5.   

Abstract

AIM: Patient-reported outcomes such as health-related quality of life (HRQoL) are main treatment goals for heart failure (HF) and therefore endpoints in multinational therapy trials. However, little is known about country-specific differences in HRQoL and in treatment-associated HRQoL improvement. The present work sought to examine those questions. METHODS AND
RESULTS: We analysed data from the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trial, in which patients from central and south-eastern Europe completed the HRQoL questionnaire SF-36 at baseline and the end of a 12-week beta-blocker up-titration (follow-up). 416 patients from Serbia (mean age 72.21 years, 69% NYHA-class I-II, 27.4% women) and 114 from Germany (mean age 73.64 years, 78.9% NYHA-class I-II, 47.4% women) were included. Controlling for clinical variables, the change in mental HRQoL from baseline to follow-up was modulated by Country: Serbian patients, M baseline = 37.85 vs. M follow-up = 40.99, t(526) = 5.34, p < .001, reported a stronger increase than Germans, M baseline = 37.66 vs. M follow-up = 38.23, t(526) = 0.68, ns. For physical HRQoL, we observed a main effect of Country, M Serbia = 39.28 vs. M Germany = 35.29, t(526) = 4.24, p < .001.
CONCLUSION: We observed significant differences in HF patients from Germany and Serbia and country-specific differences between Serbian and German patients in mean physical HRQoL. Changes in mental HRQoL were modulated by country. Those results may reflect psychological, sociocultural, aetiological differences or regional differences in phenotype prevalence. More importantly, they suggest that future multinational trials should consider such aspects when designing a trial in order to avoid uncertainties aligned to data interpretation and to improve subsequent treatment optimisation.

Entities:  

Keywords:  Beta-blocker; Heart failure; Patient-reported outcomes; Quality of life

Mesh:

Substances:

Year:  2017        PMID: 28361371     DOI: 10.1007/s00392-017-1101-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  33 in total

1.  Preferences of heart failure patients in daily clinical practice: quality of life or longevity?

Authors:  Imke H Kraai; Karin M Vermeulen; Marie Louise A Luttik; Tialda Hoekstra; Tiny Jaarsma; Hans L Hillege
Journal:  Eur J Heart Fail       Date:  2013-05-05       Impact factor: 15.534

2.  Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables.

Authors:  J Juenger; D Schellberg; S Kraemer; A Haunstetter; C Zugck; W Herzog; M Haass
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

3.  Cultural values and population health: a quantitative analysis of variations in cultural values, health behaviours and health outcomes among 42 European countries.

Authors:  Johan P Mackenbach
Journal:  Health Place       Date:  2014-05-15       Impact factor: 4.078

4.  Newly diagnosed heart failure: change in quality of life, mood, and illness beliefs in the first 6 months after diagnosis.

Authors:  K Mulligan; P A Mehta; T Fteropoulli; S W Dubrey; H F McIntyre; T A McDonagh; G C Sutton; D M Walker; M R Cowie; S Newman
Journal:  Br J Health Psychol       Date:  2011-08-25

5.  'It could be worse ... lot's worse!' Why health-related quality of life is better in older compared with younger individuals with heart failure.

Authors:  Debra K Moser; Seongkum Heo; Kyoung Suk Lee; Muna Hammash; Barbara Riegel; Terry A Lennie; Cynthia Arslanian-Engoren; Gia Mudd-Martin; Nancy Albert; John Watkins
Journal:  Age Ageing       Date:  2013-07-05       Impact factor: 10.668

6.  Assessing the impact of heart failure therapeutics on quality of life and functional capacity.

Authors:  Eldrin F Lewis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 7.  Geographic differences in heart failure trials.

Authors:  João Pedro Ferreira; Nicolas Girerd; Patrick Rossignol; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2015-07-21       Impact factor: 15.534

Review 8.  Health status as a risk factor in cardiovascular disease: a systematic review of current evidence.

Authors:  Paula M C Mommersteeg; Johan Denollet; John A Spertus; Susanne S Pedersen
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

9.  The effect of acceptance of illness on the quality of life in patients with chronic heart failure.

Authors:  Monika Obiegło; Izabella Uchmanowicz; Marta Wleklik; Beata Jankowska-Polańska; Mateusz Kuśmierz
Journal:  Eur J Cardiovasc Nurs       Date:  2015-01-08       Impact factor: 3.908

Review 10.  Drug therapy for heart failure in older patients-what do they want?

Authors:  Donah Zachariah; Jacqueline Taylor; Nigel Rowell; Clare Spooner; Paul R Kalra
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

View more
  1 in total

1.  Regional differences in heart failure hospitalizations, mortality, and readmissions in Slovenia 2004-2012.

Authors:  Daniel Omersa; Ivan Erzen; Mitja Lainscak; Jerneja Farkas
Journal:  ESC Heart Fail       Date:  2019-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.